Company research / NXTC

NextCure, Inc. (NXTC)

CIK 0001661059 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2020-12-31, NextCure, Inc. reported revenue of $22.38M. Revenue grew 252.6% from the prior annual period.

Key ratios (year ended 2020-12-31)

-184.2%
Operating margin
-163.6%
Net margin
-12.5%
Return on year-end equity
252.6%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 8-K · 2026-09-03

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.